Lupus Nephritis - Pipeline Insight, 2026

DelveInsight's, "Lupus Nephritis - Pipeline Insight, 2026" report provides comprehensive insights about 35+ companies and 42+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Lupus Nephritis: Understanding

Lupus Nephritis: Overview

Lupus nephritis is a severe manifestation of systemic lupus erythematosus (SLE) a chronic autoimmune disease that causes inflammation and damage to multiple organ systems, with the kidneys as a primary target. This condition often develops within 3 to 5 years of SLE onset and significantly increases the risk of end-stage renal disease (ESRD). Early detection of SLE through monitoring renal function, including serum creatinine levels, urine protein-to-creatinine ratios, and urinalysis, is essential for effectively managing the condition.

The symptoms of lupus nephritis are often subtle and can vary between individuals or even from day to day. Common signs include unexplained weight gain, high blood pressure, and swelling particularly around the eyes, legs, ankles, or fingers which may worsen throughout the day. Changes in urine are also typical, such as dark-colored urine, foamy or frothy appearance indicating protein loss, and increased nighttime urination. In more severe cases, the condition can progress to kidney failure if left untreated.

The pathophysiology of lupus nephritis involves a spectrum of renal lesions affecting the glomerular, tubulointerstitial, and vascular compartments. The disease is characterized by immune complex deposition in different regions of the kidney, including the mesangial, subendothelial, and subepithelial spaces, leading to structural and functional damage. Based on morphological and immunological findings from renal biopsy, lupus nephritis is classified into six classes, ranging from minimal mesangial involvement with immune deposits but normal-appearing glomeruli, to advanced sclerosing disease where most glomeruli are scarred. Intermediate forms show varying degrees of mesangial proliferation, focal or diffuse glomerular involvement, and in some cases thickening of capillary loops associated with heavy proteinuria. Among these, diffuse involvement (class IV) is the most common and carries the worst prognosis, with significant rates of treatment resistance and relapse.

The pathogenesis of lupus nephritis involves a combination of genetic, environmental, and immune system factors. The condition is primarily driven by a type III hypersensitivity reaction, which leads to the formation of immune complexes. Anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies bind to DNA, which forms anti-dsDNA immune complexes. These immune complexes deposit in the mesangium, subendothelial, or subepithelial spaces near the glomerular basement membrane, triggering an inflammatory response. This activates the complement pathway, resulting in the influx of neutrophils and other inflammatory cells, which contribute to the development of lupus nephritis.

The diagnosis of lupus nephritis is based on laboratory findings, imaging, and renal biopsy. Common laboratory features include low complement levels, positive anti-dsDNA antibodies, and urinary abnormalities such as proteinuria and hematuria, while newer markers like urinary CD163 may help detect early disease activity. Renal biopsy remains the key tool for confirming diagnosis and guiding treatment, although clinical and histological findings may not always align. Treatment and management are primarily guided by disease class and involve both pharmacological and supportive strategies. Baseline therapy includes hydroxychloroquine for all patients unless contraindicated, while mild forms (classes I and II) may only require monitoring. More severe disease (classes III, IV, and some V) requires immunosuppressive therapy, typically involving mycophenolate mofetil or cyclophosphamide combined with glucocorticoids during an induction phase aimed at achieving remission, followed by a prolonged maintenance phase using lower-dose immunosuppression to prevent relapse.

"Lupus Nephritis - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lupus Nephritis pipeline landscape is provided which includes the disease overview and Lupus Nephritis treatment guidelines. The assessment part of the report embraces, in depth Lupus Nephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lupus Nephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Lupus Nephritis R&D. The therapies under development are focused on novel approaches to treat/improve Lupus Nephritis.

Lupus Nephritis Emerging Drugs Chapters

This segment of the Lupus Nephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lupus Nephritis Emerging Drugs

• Ianalumab: Novartis

Ianalumab (VAY736) is an investigational, fully human monoclonal antibody developed by Novartis that targets the BAFF receptor to treat B-cell driven autoimmune diseases. It features a dual mechanism of action, combining B-cell depletion via antibody-dependent cellular cytotoxicity (ADCC) with inhibition of B-cell survival signals. Ianalumab has shown promise in treating autoimmune diseases such as lupus nephritis, immune thrombocytopenia (ITP), and Sjogren's syndrome. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Lupus Nephritis.

• HSK39297: Haisco Pharmaceutical Group Co., Ltd.

HSK39297 is a novel, oral, highly selective, and potent Factor B (CFB) inhibitor targeting the alternative complement pathway. As a CFB inhibitor, HSK39297 blocks the complement alternative pathway, preventing the amplification of inflammatory cascades and reducing C3 deposition in kidneys. The drug is being developed for PNH (a rare hematologic disorder) and complement-mediated glomerular diseases such as IgA nephropathy, C3 nephropathy, and lupus nephritis. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Lupus Nephritis.

• CNTY101: Century Therapeutics, Inc.

CNTY-101 is an investigational off-the-shelf cancer immunotherapy product candidate that utilizes iPSC-derived natural killer (NK) cells with a CD19-directed chimeric antigen receptor (CAR) and includes Century's core Allo-Evasion(TM) edits designed to overcome the three major pathways of host versus graft rejection CD8+ T cells, CD4+ T cells and NK cells. In addition, the product candidate is engineered to express IL-15 to provide homeostatic cytokine support, which has been shown pre-clinically to improve functionality and persistence. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Lupus Nephritis.

Lupus Nephritis: Therapeutic Assessment

This segment of the report provides insights about the different Lupus Nephritis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Lupus Nephritis
• There are approx. 35+ key companies which are developing the therapies for Lupus Nephritis. The companies which have their Lupus Nephritis drug candidates in the most advanced stage, i.e. Phase III include, Novartis.
• Phases

DelveInsight's report covers around 42+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lupus Nephritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lupus Nephritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lupus Nephritis drugs.

Lupus Nephritis Report Insights

• Lupus Nephritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lupus Nephritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lupus Nephritis drugs?
• How many Lupus Nephritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lupus Nephritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lupus Nephritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lupus Nephritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Haisco Pharmaceutical Group Co., Ltd.
• Century Therapeutics, Inc.
• Hinge Bio
• Synthekine
• Artiva Biotherapeutics, Inc.
• CRISPR Therapeutics
• Curocell Inc.
• AbelZeta Inc.
• Cabaletta Bio
• Kyverna Therapeutics
• iCell Gene Therapeutics
• Nkarta, Inc.
• Fosun Pharma
• Vertex Pharmaceuticals

Key Products

• Ianalumab
• HSK39297
• CNTY101
• HB2198
• SYNCAR-001
• AB-101
• CTX112
• CRC01
• C-CAR168
• CABA-201
• KYV-101
• ICG318
• NKX019
• HLX79
• Povetacicept